Search Results - "Sikov, W. M"

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer by Nahleh, Z. A., Barlow, W. E., Hayes, D. F., Schott, A. F., Gralow, J. R., Sikov, W. M., Perez, E. A., Chennuru, S., Mirshahidi, H. R., Corso, S. W., Lew, D. L., Pusztai, L., Livingston, R. B., Hortobagyi, G. N.

“…SWOG S0800, a randomized open-label Phase II clinical trial, compared the combination of weekly nab-paclitaxel and bevacizumab followed by dose-dense…”
Get full text

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial by Geyer, C.E., Sikov, W.M., Huober, J., Rugo, H.S., Wolmark, N., O’Shaughnessy, J., Maag, D., Untch, M., Golshan, M., Lorenzo, J. Ponce, Metzger, O., Dunbar, M., Symmans, W.F., Rastogi, P., Sohn, J.H., Young, R., Wright, G.S., Harkness, C., McIntyre, K., Yardley, D., Loibl, S.

“…Primary analyses of the phase III BrighTNess trial showed addition of carboplatin with/without veliparib to neoadjuvant chemotherapy significantly improved…”
Get full text

Reply to the Letter to the Editor ‘Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple-negative breast cancer’ by A. Okines and N. Turner by Geyer, C.E., Sikov, W.M., Loibl, S.

Get full text

Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study by Lopresti, M. L., Bian, J. J., Sakr, B. J., Strenger, R. S., Legare, R. D., Fenton, M., Witherby, S. M., Dizon, D. S., Pandya, S. V., Stuckey, A. R., Edmondson, D. A., Gass, J. S., Emmick, C. M., Graves, T. A., Cutitar, M., Olszewski, A. J., Sikov, W. M.

“…Purpose In HER2-positive breast cancer (HER2+ BC), neoadjuvant chemotherapy (NACT) with dual HER2-targeted therapy achieves high pathologic complete response…”
Get full text

Multicentric warfarin‐induced skin necrosis complicating heparin‐induced thrombocytopenia by Warkentin, Theodore E., Sikov, William M., Lillicrap, David P.

“…Two patients developed catastrophic multicentric skin necrosis while receiving warfarin to treat venous thromboembolism complicated by immune‐mediated…”
Get full text

Spontaneous venous thrombosis in a young patient with combined factor V Leiden and lupus anticoagulant by Lopez, Francisco F., Sweeney, Joseph D., Blair, Abbe J., Sikov, William M.

“…We describe a case of a 28‐year‐old man who developed an extensive spontaneous deep venous thrombosis. Testing revealed heterozygotic factor V Leiden mutation,…”
Get full text

Splenosis presenting as occult gastrointestinal bleeding by Sikov, William M., Schiffman, Fred J., Weaver, Michael, Dyckman, Jacob, Shulman, Richard, Torgan, Philip

“…A 48‐year‐old man presented with recurrent gastrointestinal bleeding and anemia. Routine endoscopic evaluation was nondiagnostic. Angiography demonstrated…”
Get full text

Weekly paclitaxel as a radiation sensitizer for locally advanced gastric and pancreatic cancers: the Brown University Oncology Group experience by Sikov, W M, Safran, H

“…Many patients with cancer of the stomach or pancreas have locally advanced, unresectable disease at diagnosis or will develop an early local or regional…”
Get full text

Locally advanced breast cancer by Sikov, W M

“…Over the past 20 years, the prognosis for women diagnosed with locally advanced breast cancer (LABC; clinical stages IIB through IIIB) has improved…”
Get full text

Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report by Akerley, W, Sikov, W M, Cummings, F, Safran, H, Strenger, R, Marchant, D

“…The optimal dose and schedule for paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in the treatment of patients with advanced breast cancer are…”
Get more information

Recent advances in medical oncology--1995-1996 by Sikov, W M

Get more information

SWOG S0800 by Pusztai, L, Hayes, D. F, Hortobagyi, G. N, Perez, E. A, Chennuru, S, Corso, S. W, Livingston, R. B, Gralow, J. R, Mirshahidi, H. R, Schott, A. F, Nahleh, Z. A, Lew, D. L, Sikov, W. M, Barlow, W. E

“…SWOG S0800, a randomized open-label Phase II clinical trial, compared the combination of weekly nab-paclitaxel and bevacizumab followed by dose-dense…”
Get full text

SWOG S0800 rates in inflammatory or locally advanced breast cancer by Nahleh, Z. A, Barlow, W. E, Hayes, D. F, Schott, A. F, Gralow, J. R, Sikov, W. M, Perez, E. A, Chennuru, S, Mirshahidi, H. R, Corso, S. W, Lew, D. L, Pusztai, L, Livingston, R. B, Hortobagyi, G. N

“…SWOG S0800, a randomized open-label Phase II clinical trial, compared the combination of weekly nab-paclitaxel and bevacizumab followed by dose-dense…”
Get full text

Evaluation of ER/PR and HER2 status by RNA sequencing in tissue core biopsies from preoperative clinical trial specimens by Kamalakaran, S., Lezon-Geyda, K., Varadan, V., Banerjee, N., Lannin, D. R., Rizack, T., Sikov, W. M., Abu-Khalaf, M. M., Janevski, A., Harris, L.

“…Abstract only 46 Background: Next-generation sequencing for measuring RNA (RNASeq) offer increased sensitivity, dynamic range and provide unbiased detection of…”
Get full text

Carboplatin (Cb), weekly nanoparticle, albumin-bound paclitaxel (wAb), and bevacizumab (Av) neoadjuvant chemotherapy (NAC) in HER2-negative breast cancer (BrCA): A BrUOG study by Sinclair, N., Abu-Khalaf, M. M., Sakr, B. J., Rizack, T., Lannin, D. R., Gass, J. S., Strenger, R., Bossuyt, V., Fenton, M. A., Harris, L., Sikov, W. M.

“…Abstract only…”
Get full text

Neoadjuvant therapy for stage II-III breast cancer with weekly nab-paclitaxel, every-three-week carboplatin, and targeted agents: Interim dose delivery and toxicity data by Rizack, T., Abu-Khalaf, M. M., Legare, R. D., Strenger, R., Fenton, M. A., Sakr, B. J., Kennedy, T. A., Harris, L., Sikov, W. M.

“…Abstract only…”
Get full text

Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer by Sikov, W. M., Perou, C. M., Golshan, M., Collyar, D., Berry, D. A., Hahn, O. M., Singh, B., Hudis, C., Winer, E. P.

“…Abstract only…”
Get full text

“Weighing in” on screening mammography by Sikov, W. M., Berz, D., Colvin, G., McCormack, E., Weitzen, S.

“…Abstract only…”
Get full text

Abstract PD3-04: Analysis of ERBB2 (HER2) amplification by ctDNA in a phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib in women with metastatic disease with initially diagnosed HER2+ breast cancer: NSABP FB-10 by Abraham, J, Puhalla, SL, Sikov, WM, Montero, AJ, Salkeni, MA, Razaq, WA, Beumer, JH, Kiesel, BF, Buyse, ME, Adamson, LM, Srinivasan, A, Pogue-Geile, KL, Allegra, CJ, Nagy, RJ, Jacobs, SA

“…Abstract Background: In this phase Ib study, the activity of T-DM1 plus N was assessed in patients (pt) previously treated with trastuzumab, pertuzumab, and a…”
Get full text

Recent developments in medical oncology by Sikov, W M, Siegel, R D

Get more information